niacinamide has been researched along with Parkinson Disease in 27 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The primary outcome was safety, defined as the frequency of moderate and severe adverse events." | 3.30 | NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. ( Af Geijerstam, SA; Berven, H; Dölle, C; Haugarvoll, K; Kverneng, S; Sheard, E; Skeie, GO; Søgnen, M; Tzoulis, C, 2023) |
| " To estimate the N-methylation ability for azaheterocyclic amines in parkinsonian patient, nicotinamide was dosed with 100 mg to 26 parkinsonians and 20 controls consisted of 16 other neurogenic disease patients and 4 healthy volunteers." | 2.69 | N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test. ( Aoyama, K; Fukushima, S; Hayase, N; Kobayashi, S; Matsubara, K; Ohta, S; Okada, K; Satomi, M; Shimizu, K; Shiono, H; Uezono, T; Yamaguchi, S, 2000) |
| "This increase may be part genetic predisposition, and part induction, by excessive exposure to its substrates (particularly nicotinamide) or stress." | 2.43 | Parkinson's disease: the first common neurological disease due to auto-intoxication? ( Cartwright, LS; Ramsden, DB; Williams, AC, 2005) |
| "Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD." | 2.42 | Bioenergetic approaches for neuroprotection in Parkinson's disease. ( Beal, MF, 2003) |
| "Parkinson's disease was induced by injection of MPTP in adult male C57BL/6 mice, nicotinamide (500 mg/kg,i." | 1.38 | [Protective effect of nicotinamide in a mouse Parkinson's disease model]. ( Jin, JH; Liang, J; Lu, Y; Luo, JH; Xu, J; Xu, SQ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (14.81) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 6 (22.22) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Brakedal, B | 1 |
| Dölle, C | 2 |
| Riemer, F | 1 |
| Ma, Y | 1 |
| Nido, GS | 1 |
| Skeie, GO | 2 |
| Craven, AR | 1 |
| Schwarzlmüller, T | 1 |
| Brekke, N | 1 |
| Diab, J | 1 |
| Sverkeli, L | 1 |
| Skjeie, V | 1 |
| Varhaug, K | 1 |
| Tysnes, OB | 1 |
| Peng, S | 1 |
| Haugarvoll, K | 2 |
| Ziegler, M | 1 |
| Grüner, R | 1 |
| Eidelberg, D | 1 |
| Tzoulis, C | 2 |
| Talavera Andújar, B | 1 |
| Aurich, D | 1 |
| Aho, VTE | 1 |
| Singh, RR | 1 |
| Cheng, T | 1 |
| Zaslavsky, L | 1 |
| Bolton, EE | 1 |
| Mollenhauer, B | 1 |
| Wilmes, P | 1 |
| Schymanski, EL | 1 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Delignat-Lavaud, B | 1 |
| Kano, J | 1 |
| Ducrot, C | 1 |
| Massé, I | 1 |
| Mukherjee, S | 1 |
| Giguère, N | 1 |
| Moquin, L | 1 |
| Lévesque, C | 1 |
| Burke, S | 1 |
| Denis, R | 1 |
| Bourque, MJ | 1 |
| Tchung, A | 1 |
| Rosa-Neto, P | 1 |
| Lévesque, D | 1 |
| De Beaumont, L | 1 |
| Trudeau, LÉ | 1 |
| Berven, H | 1 |
| Kverneng, S | 1 |
| Sheard, E | 1 |
| Søgnen, M | 1 |
| Af Geijerstam, SA | 1 |
| Willyard, C | 1 |
| Schöndorf, DC | 1 |
| Ivanyuk, D | 1 |
| Baden, P | 1 |
| Sanchez-Martinez, A | 1 |
| De Cicco, S | 1 |
| Yu, C | 1 |
| Giunta, I | 1 |
| Schwarz, LK | 1 |
| Di Napoli, G | 1 |
| Panagiotakopoulou, V | 1 |
| Nestel, S | 1 |
| Keatinge, M | 1 |
| Pruszak, J | 1 |
| Bandmann, O | 1 |
| Heimrich, B | 1 |
| Gasser, T | 1 |
| Whitworth, AJ | 1 |
| Deleidi, M | 1 |
| Lehmann, S | 1 |
| Costa, AC | 1 |
| Celardo, I | 1 |
| Loh, SH | 1 |
| Martins, LM | 1 |
| Wallach, I | 1 |
| Jaitly, N | 1 |
| Lilien, R | 1 |
| Liu, Z | 1 |
| Hamamichi, S | 1 |
| Lee, BD | 1 |
| Yang, D | 1 |
| Ray, A | 1 |
| Caldwell, GA | 1 |
| Caldwell, KA | 1 |
| Dawson, TM | 1 |
| Smith, WW | 1 |
| Dawson, VL | 1 |
| Xu, J | 1 |
| Xu, SQ | 1 |
| Liang, J | 1 |
| Lu, Y | 1 |
| Luo, JH | 1 |
| Jin, JH | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Beal, MF | 1 |
| Williams, AC | 5 |
| Ramsden, DB | 3 |
| Cartwright, LS | 1 |
| Willets, JM | 1 |
| Lunec, J | 1 |
| Griffiths, HR | 1 |
| Pall, HS | 1 |
| Steventon, GB | 1 |
| Green, S | 2 |
| Buttrum, S | 2 |
| Molloy, H | 2 |
| Waring, RH | 1 |
| Fukushima, T | 3 |
| Tawara, T | 1 |
| Isobe, A | 1 |
| Hojo, N | 1 |
| Shiwaku, K | 1 |
| Yamane, Y | 1 |
| Aoyama, K | 1 |
| Matsubara, K | 1 |
| Okada, K | 1 |
| Fukushima, S | 1 |
| Shimizu, K | 1 |
| Yamaguchi, S | 1 |
| Uezono, T | 1 |
| Satomi, M | 1 |
| Hayase, N | 1 |
| Ohta, S | 1 |
| Shiono, H | 1 |
| Kobayashi, S | 1 |
| Kaetsu, A | 1 |
| Lim, H | 1 |
| Moriyama, M | 1 |
| Steventon, G | 1 |
| Sturman, S | 1 |
| Waring, R | 1 |
| Pall, H | 1 |
| Williams, A | 1 |
| Tzavellas, O | 1 |
| Torizuka, K | 1 |
| Hamamoto, K | 1 |
| Morita, R | 1 |
| Mukai, T | 1 |
| Kosaka, T | 1 |
| Handa, J | 1 |
| Nishitani, H | 1 |
| Cotzias, GC | 1 |
| Lawrence, WH | 1 |
| Papavasiliou, PS | 1 |
| Düby, SE | 1 |
| Braĭko, IV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NOPARK Open Label Extension Study[NCT05546567] | 400 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | |||
| NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease[NCT03816020] | 30 participants (Actual) | Interventional | 2019-03-09 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niacinamide and Parkinson Disease
| Article | Year |
|---|---|
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
Bioenergetic approaches for neuroprotection in Parkinson's disease.
Topics: Acetylcarnitine; Coenzymes; Creatine; Energy Metabolism; Free Radicals; Ginkgo biloba; Humans; Mitoc | 2003 |
Autotoxicity, methylation and a road to the prevention of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Humans; Methylation; Niacina | 2005 |
Parkinson's disease: the first common neurological disease due to auto-intoxication?
Topics: Brain; Environment; Genetic Predisposition to Disease; Humans; Inactivation, Metabolic; Methyltransf | 2005 |
[Elucidation of paraquat poisoning mechanism and development of the neuronal death model].
Topics: Animals; Chaperonin 60; Disease Models, Animal; Electron Transport Complex I; Herbicides; Humans; Li | 2002 |
3 trials available for niacinamide and Parkinson Disease
| Article | Year |
|---|---|
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2022 |
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2022 |
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2022 |
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2022 |
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.
Topics: Double-Blind Method; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2023 |
N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test.
Topics: Aged; Aging; Aldehyde Oxidase; Aldehyde Oxidoreductases; Brain; Carbolines; Chromatography, High Pre | 2000 |
19 other studies available for niacinamide and Parkinson Disease
| Article | Year |
|---|---|
Studying the Parkinson's disease metabolome and exposome in biological samples through different analytical and cheminformatics approaches: a pilot study.
Topics: Aged; Alanine; Betaine; Cheminformatics; Exposome; Humans; Metabolome; Metabolomics; Neurodegenerati | 2022 |
Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice.
Topics: Animals; Caffeine; Calcium; Corpus Striatum; Dopamine; Mice; Neostriatum; Niacinamide; Parkinson Dis | 2023 |
How gut microbes could drive brain disorders.
Topics: alpha-Synuclein; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Autism Spectrum Disorder | 2021 |
The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease.
Topics: Animals; Autophagy; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasm | 2018 |
Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease.
Topics: Animals; Blotting, Western; Brain; Dietary Supplements; Disease Models, Animal; Dopaminergic Neurons | 2016 |
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways.
Topics: Breast Neoplasms; Computational Biology; Databases, Factual; Diabetes Mellitus, Type 2; Drug-Related | 2010 |
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Topics: Animals; Animals, Genetically Modified; Benzenesulfonates; Caenorhabditis elegans; Cell Survival; Di | 2011 |
[Protective effect of nicotinamide in a mouse Parkinson's disease model].
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred C57BL; Motor Ac | 2012 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases.
Topics: Animals; Choline; Embryonic Development; Epigenesis, Genetic; Evolution, Molecular; Homeostasis; Hum | 2005 |
Neurotoxicity of nicotinamide derivatives: their role in the aetiology of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; Humans; Isomerism; Kinetics; L-Lactate Dehydrog | 1993 |
N-methylation of pyridines and Parkinson's disease.
Topics: Humans; Methylation; Methyltransferases; Niacinamide; Parkinson Disease; Pyridines; Pyridones | 1993 |
Radical formation site of cerebral complex I and Parkinson's disease.
Topics: Animals; Brain; Cattle; Electrophoresis, Polyacrylamide Gel; Hydrogen-Ion Concentration; Hydroxyl Ra | 1995 |
Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease.
Topics: Animals; Brain; Cell Fractionation; Cytosol; Dopamine; Dose-Response Relationship, Drug; Gas Chromat | 2002 |
N-methylation of pyridines in Parkinson's disease.
Topics: Humans; Methylation; Middle Aged; Niacinamide; Parkinson Disease | 1991 |
[The effect of vitamin B 12 in combination with 4-chlortestosterone acetate on Parkinson's syndrome and hyperkinesia].
Topics: Adult; Aged; Blood Pressure; Body Weight; Drug Tolerance; Female; Folic Acid; Humans; Hyperkinesis; | 1967 |
Regional cerebral blood flow measurement with xenon 133 and the scinticamera.
Topics: Adult; Aged; Arteriosclerosis; Brain; Cerebrovascular Circulation; Computers; Female; Humans; Hydroc | 1971 |
Nicotinamide ineffective in parkinsonism.
Topics: Adult; Humans; Hypotension; Middle Aged; Niacinamide; Parkinson Disease | 1972 |
[Phenatine treatment of parkinsonism].
Topics: Adult; Humans; Male; Middle Aged; Niacinamide; Parkinson Disease | 1973 |